An economic evaluation of the war on cancer

Aldy, J.E., Viscusi, W.K., 2007. Age Differences in the Value of Statistical Life: Revealed Preference Evidence, Resources For the Future, Discussion Papers. American Cancer Society, 2008. Cancer Facts and Figures 2008. American Cancer Society, Atlanta. Becker, G.S., Murphy, K.M., Philipson, T.J., 2007. The Value of Life Near Its End and Terminal Care. National Bureau of Economic Research Working Paper 1333. Cambridge, MA. Becker, 2005, The quantity and quality of life and the evolution of world inequality, American Economic Review, 95, 277, 10.1257/0002828053828563 Berenson, 2005 Berndt, 1996, Pharmaceutical innovations and market dynamics: Tracing effects on price indexes for antidepressant drugs, Brookings Papers on Economic Activity, 133, 10.2307/2534748 Black, 2002, All-cause mortality in randomized trials of cancer screening, Journal of National Cancer Institute, 94, 167, 10.1093/jnci/94.3.167 Blinder, 1973, Wage discrimination: Reduced form and structural estimates, Journal of Human Resources, 8, 436, 10.2307/144855 Bloom, 1962, Natural history of untreated breast cancer (1805–1933). Comparison of untreated and treated cases according to histological grade of malignancy, British Medical Journal, 2, 213, 10.1136/bmj.2.5299.213 Breen, 2001, Progress in cancer screening over a decade: results of cancer screening from the 1987, 1992, and 1998 National Health Interview Surveys, Journal of the National Cancer Institute, 93, 1704, 10.1093/jnci/93.22.1704 Caves, 1991, Patent expiration, entry, and competition in the u s pharmaceutical industry, Brookings Papers on Economic Activity, 1, 10.2307/2534790 Cutler, 1997, Measuring the Health of the U.S. Population, Brookings Papers on Economic Activity, 217, 10.2307/2534757 Devlin, 2004, Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis, Health Economics, 13, 437, 10.1002/hec.864 DiMasi, 2003, The price of innovation: New estimates of drug development costs, Journal of Health Economics, 22, 151, 10.1016/S0167-6296(02)00126-1 Epstein, 2005 Espey, 2007, Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives, Cancer, 110, 2119, 10.1002/cncr.23044 Faguet, 2005 Gaynor, 2003, Competition among Hospitals, Rand Journal of Economics, 34, 764, 10.2307/1593787 Goldman, 2010, The value of specialty oncology drugs, Health Services Research, 45, 115, 10.1111/j.1475-6773.2009.01059.x Grabowski, 1992, Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act, Journal of Law and Economics, 35, 331, 10.1086/467257 Hall, 2007, The value of life and the rise in health spending, Quarterly Journal of Economics, 122, 39, 10.1162/qjec.122.1.39 Hillner, 2007, Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?, Journal of Clinical Oncology, 25, 611, 10.1200/JCO.2006.09.3542 Honore, 2006, Bounds in competing risks models and the war on cancer, Econometrica, 74, 1675, 10.1111/j.1468-0262.2006.00722.x Jaffe, 1996, Trends and patterns in research and development expenditures in the United States, Proceedings of the National Academy of Sciences of the United States of America, 93, 12658, 10.1073/pnas.93.23.12658 Kolata, 2008 Lee, 2009, An empirical estimate of the value of life: Updating the renal dialysis cost-effectiveness standard, Value in Health, 12, 80, 10.1111/j.1524-4733.2008.00401.x Lichtenberg, F.R., 2004. The Expanding Pharmaceutical Arsenal in the War on Cancer. National Bureau of Economic Research, Inc, NBER Working Papers. Mokdad, 2003, Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001, JAMA, 289, 76, 10.1001/jama.289.1.76 Moy, 2001, Cause-specific mortality coding. methods in the collaborative ocular melanoma study coms report no. 14, Controlled Clinical Trials, 22, 248, 10.1016/S0197-2456(01)00113-1 Murphy, 2006, The value of health and longevity, Journal of Political Economy, 114, 871, 10.1086/508033 Nadler, 2006, Do oncologists believe new cancer drugs offer good value?, The Oncologist, 11, 90, 10.1634/theoncologist.11-2-90 Oaxaca, 1973, Male–female wage differentials in urban labor markets, International Economic Review, 14, 693, 10.2307/2525981 Philipson, 2006, Who benefits from new medical technologies? Estimates of consumer and producer surpluses for HIV/AIDS drugs, Forum for Health Economics & Policy, 9, 10.2202/1558-9544.1005 Pulte, 2008, Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century, Archives of Internal Medicine, 168, 469, 10.1001/archinternmed.2007.125 Raz, 2007, Natural history of stage I non-small cell lung cancer, Chest, 132, 193, 10.1378/chest.06-3096 Shih, 2008, Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean?, CA: A Cancer Journal for Clinicians, 58, 231, 10.3322/CA.2008.0008 Sun, 2010, The contributions of improved therapy and earlier detection to cancer survival gains, 1988–2000, Forum for Health Economics and Policy, 13, 10.2202/1558-9544.1195 Welch, 2000, Are increasing 5-year survival rates evidence of success against cancer?, JAMA, 283, 2975, 10.1001/jama.283.22.2975